A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study
To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison
To Interferon Beta-1a (Rebif®) In Patients With Relapsing
Multiple Sclerosis This study will evaluate whether or not
individuals diagnosed with a relapsing form of multiple
sclerosis (MS) treated with an investigational drug called
ocrelizumab (o-cree-liz-u-mab) experience fewer clinical
relapses (recurrences) compared to those treated with Rebif®
(interferon beta 1a), an approved drug for MS. Ocrelizumab is an
experimental drug, which means that it is still being tested and
is not yet approved by the US Food and Drug Administration
(FDA). This study will also evaluate the safety of ocrelizumab
compared to that of Rebif®. MS is an autoimmune disease where
the body’s immune system attacks and damages myelin. This is the
substance that surrounds and protects the nerve fibers in the
central nervous system. The nerve fibers themselves can also be
damaged. Scar tissue (sclerosis) results